chufangao/CTO huggingface dataset:
Clinical trial NCT05126329: Pharmacokinetics of Amcenestrant in Female Hepatic Impaired Participants as Compared to Participants With Normal Hepatic Function
Official title: An Open-label Pharmacokinetic and Tolerability Study of Amcenestrant Given as a Single Dose in Female Participants With Mild and Moderate Hepatic Impairment, and in Matched Participants With Normal Hepatic Function
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor decision to prematurely stop the study, not linked to any safety concern
Enrollment: 13.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-11-15
Primary completion date: 2022-05-16
Completion date: 2022-05-16
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT04281472: A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
Official title: A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Acronym: ADHERE
Sponsor: argenx (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 322.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-15
Primary completion date: 2023-05-11
Completion date: 2023-05-11
Baseline population: A total of 322 participants received efgartigimod PH20 SC in Stage A, and 221 of the 322 participants were randomized in a 1:1 ratio to efgartigimod PH20 SC (N=111) or placebo (N=110) in Stage B. Therefore, the total number of participants was 322, not 543 which was automatically calculated.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04065841: Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.
Official title: A Randomized, Double-blind, Parallel-group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Oral Tropifexor (LJN452) & Licogliflozin (LIK066) Combination Therapy and Each Monotherapy, Compared With Placebo for Treatment of Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis.(ELIVATE)
Acronym: ELIVATE
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The sponsor made a business decision to stop development of the trial drugs. The decision to stop the trial early was not because of any safety concerns.
Enrollment: 234.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-12-30
Primary completion date: 2022-10-27
Completion date: 2022-10-27
Baseline population: Full Analysis Set (FAS): all participants to whom study treatment was assigned by randomization and were treated
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT02598999: Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients
Official title: Randomized, Double Blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics After Single Ascending Doses or Multiple Ascending Doses of OSCN-, bLF or ALX-009 in Healthy Male and CF and Non-CF Bronchiectasis Patients
Sponsor: Alaxia SAS (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Financial issues
Enrollment: 92.0 (ACTUAL)
Number of arms: 4.0
Start date: 2015-11-30
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Clinical trial NCT04349371: Saved From COVID-19 - Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID
Official title: Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low enrollment.
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-21
Primary completion date: 2021-02-11
Completion date: 2021-02-11
Baseline population: The study was terminated before participants could be assigned to any Arm.
Limitations and caveats: Study was stopped early due to poor enrollment. Data was not collected and therefore not analyzed.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02940223: Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer
Official title: Effects of Fish Oil and Physical Activity on Fatigue in Patients With Advanced Cancer
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: PI is requesting termination (closure) of this study.
Enrollment: 2.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-03-16
Primary completion date: 2020-11-24
Completion date: 2020-11-24
Baseline population: A total of 2 participants were recruited before the study was aborted due to low accrual.
Clinical trial NCT05081271: COVID-19 Booster Vaccination in Persons With Multiple Sclerosis
Official title: COVID-19 Booster Vaccination in Persons With Multiple Sclerosis
Sponsor: Griffin Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Most potential participants had already received their booster vaccinations outside of the study
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-15
Primary completion date: 2022-05-30
Completion date: 2022-05-30
Plan to share individual participant data: YES
IPD sharing description: De-identified requests for IPD that underlie results in a publication will be made available to other researchers upon requests sent to the study PI.
IPD time frame: IPD will be shared upon request following publication of our findings.
IPD access criteria: The study PI will review and address requests for IPD.
Clinical trial NCT06085638: Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia
Official title: Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Zero participants accrued
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-09-14
Primary completion date: 2023-10-20
Completion date: 2023-10-20
Clinical trial NCT02890368: Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Official title: A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Enrollment: 56.0 (ACTUAL)
Number of arms: 7.0
Start date: 2016-09-30
Primary completion date: 2020-03-31
Completion date: 2020-03-31
Plan to share individual participant data: NO
Clinical trial NCT03721965: Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects
Official title: An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Pediatric Subjects
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study was terminated due to insufficient efficacy in a separate phase III study
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-31
Primary completion date: 2020-02-17
Completion date: 2020-02-17
Plan to share individual participant data: NO
Clinical trial NCT04493242: Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS
Official title: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Phase II Clinical Trial
Acronym: EXIT-COVID19
Sponsor: Direct Biologics, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 102.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-09-24
Primary completion date: 2021-05-01
Completion date: 2021-05-22
Baseline population: The Safety Analysis Set consisted of all participants who received any study drug.
Plan to share individual participant data: NO
Clinical trial NCT03283631: Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM
Official title: INTERCEPT: INTracerebral EGFR-vIII Chimeric Antigen Receptor Gene-Modified T CElls for PaTients With Recurrent GBM
Acronym: INTERCEPT
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: We are halting enrollment of this study.
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-05-30
Primary completion date: 2019-09-19
Completion date: 2020-06-30
Clinical trial NCT04866069: Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults
Official title: Phase I Study Evaluating the Safety and Efficacy of the Protective Adjuvanted Inactivated Vaccine Developed Against SARS-CoV-2 in Healthy Participants, Administered as Two Injections Subcutaneously in Two Different Dosages.
Acronym: COVID-19
Sponsor: The Scientific and Technological Research Council of Turkey (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Although cellular responses to virus were satisfactory, neutralizing titres against virus were lower then expected levels
Enrollment: 50.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-04-25
Primary completion date: 2021-09-05
Completion date: 2021-09-05
Plan to share individual participant data: NO
Clinical trial NCT04823052: Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40
Official title: A Phase 2, Placebo-controlled, Adaptive Design Study to Explore the Safety and Efficacy of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) and Possible Other Treatments in Adolescent and Adult Males With Fragile X Syndrome (FXS)
Acronym: IMPACT-FXS
Sponsor: Healx Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Healx has experienced delays to the site activation of the study and this has had an adverse impact on the recruitment timeline which is delaying the progress of other projects in our FXS programme.
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-05-25
Primary completion date: 2022-10-19
Completion date: 2022-10-19
Clinical trial NCT03345810: Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
Official title: Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
Acronym: DURATION
Sponsor: AIO-Studien-gGmbH (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 200.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-12-14
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT02431663: Ketamine in Refractory Convulsive Status Epilepticus
Official title: Efficacy of Ketamine in Refractory Convulsive Status Epilepticus in Children: a Multicenter, Randomized, Controlled, Open-label, No-profit, With Sequential Design Study.
Acronym: KETASER01
Sponsor: Meyer Children's Hospital IRCCS (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Futility
Enrollment: 57.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-04-30
Primary completion date: 2020-03-31
Completion date: 2020-03-31
Clinical trial NCT04415151: Tofacitinib for Treatment of Moderate COVID-19
Official title: Investigation of Tofacitinib to Mitigate the Impact of COVID-19 (I-TOMIC) in Moderate SARS-CoV-2 (MODERATE I-TOMIC)
Acronym: I-TOMIC
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study terminated due to lack of enrollment reflecting the decrease in number of COVID infections. There were no safety and/or efficacy concerns involved in the decision to stop enrollment.
Enrollment: 24.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-14
Primary completion date: 2021-02-28
Completion date: 2021-02-28
Plan to share individual participant data: NO
Clinical trial NCT01963832: RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke
Official title: RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: not funded
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2016-11-30
Primary completion date: 2020-11-30
Completion date: 2021-11-30
Clinical trial NCT03959241: TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)
Official title: A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN 1801; Mi-Immune)
Acronym: 1703/1801
Sponsor: Medical College of Wisconsin (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 431.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-25
Primary completion date: 2022-09-19
Completion date: 2022-09-19
Baseline population: Baseline Analysis Population includes all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).
IPD time frame: Within 6 months of official study closure at participating sites.
IPD access criteria: Available to the public
Clinical trial NCT04798989: A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology
Official title: A Phase 2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CY6463 When Administered to Participants With Alzheimer's Disease and Vascular Pathology
Sponsor: Tisento Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to enrollment challenges
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-01
Primary completion date: 2022-11-28
Completion date: 2022-11-28
Plan to share individual participant data: NO
Clinical trial NCT04642079: Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age
Official title: A PHASE 3, SINGLE-ARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 839.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-12-04
Primary completion date: 2022-04-06
Completion date: 2022-04-06
Baseline population: Enrolled population included all participants who signed informed consent form (ICF).
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT02955524: Topical Anesthesia and Intra-arterial Chemotherapy for Retinoblastoma
Official title: Topical Anesthesia to Decrease the Trigeminal-Cardiac Reflex During Intra-arterial Injection of Chemotherapy for Retinoblastoma in Children.
Acronym: TOPIAC
Sponsor: University of Miami (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: I discontinued this study because I transferred to another institution.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-03-31
Primary completion date: 2020-06-30
Completion date: 2020-12-31
Plan to share individual participant data: NO
Clinical trial NCT01490580: Premedication Trial for Tracheal Intubation of the NEOnate
Official title: Double Blind Randomized Controlled Trial Comparing Atropine+Propofol Versus Atropine+Atracurium+Sufentanil as a Premedication Prior to Semi-urgent or Elective Endotracheal Intubation of Term and Preterm Newborns
Acronym: PRETTINEO
Sponsor: Centre Hospitalier Intercommunal Creteil (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 173.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-05-31
Primary completion date: 2016-08-31
Completion date: 2020-04-15
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03072771: Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Official title: A Pilot Trial of Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With DLBCL
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 14.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-08-01
Primary completion date: 2021-04-07
Completion date: 2023-10-30
Plan to share individual participant data: NO
Clinical trial NCT04504916: A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
Official title: A Phase 2 Study of VLS-101 in Patients With Solid Tumors
Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Business reasons
Enrollment: 102.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-10-07
Primary completion date: 2023-06-12
Completion date: 2023-06-12
Limitations and caveats: Study terminated due to business reasons
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pd
Clinical trial NCT03829878: Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT)
Official title: A Randomized Double-Blind Placebo Controlled Cross-Over Study of CP101 (Full-Spectrum Microbiota®) in Children With Autism Spectrum Disorder and Associated Gastrointestinal Symptoms
Acronym: SPROUT
Sponsor: Finch Research and Development LLC. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study not started
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-31
Primary completion date: 2020-05-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT04803123: Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL
Official title: Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in Relapsed or Refractory Adult B-cell Acute Lymphoblastic Leukemia
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Sponsor halted clinical development of study drug
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-06-21
Primary completion date: 2023-04-03
Completion date: 2023-04-26
Plan to share individual participant data: NO
Clinical trial NCT02288377: A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
Official title: A EUROPEAN, MULTICENTRE, PHASE II/III RANDOMISED DOUBLE-BLIND, PLACEBO CONTROLLED STUDY EVALUATING LANREOTIDE AS MAINTENANCE THERAPY IN PATIENTS WITH NON-RESECTABLE DUODENO-PANCREATIC NEUROENDOCRINE TUMOURS AFTER FIRST-LINE TREATMENT
Acronym: REMINET
Sponsor: Federation Francophone de Cancerologie Digestive (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Because of slow recruitment
Enrollment: 53.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-01-31
Primary completion date: 2020-01-31
Completion date: 2020-01-31
Baseline population: Baseline population is the Intent-to-treat population, all the patients randomized.
Clinical trial NCT03716570: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease
Official title: A Multicenter, Blinded, Placebo-Controlled, Randomized, Single and Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Subjects With Parkinson's Disease
Sponsor: Biogen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Affiliated study NCT03318523 did not meet its primary outcome measure of change from baseline measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and did not demonstrate efficacy on secondary outcome measures
Enrollment: 24.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-03-12
Primary completion date: 2021-04-23
Completion date: 2021-04-23
Plan to share individual participant data: YES
IPD sharing description: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/
Clinical trial NCT03963401: A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis
Official title: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PF-06700841 TO EVALUATE THE EFFICACY AT 16 WEEKS AND TO EVALUATE THE SAFETY AND EFFICACY UP TO 1 YEAR IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 219.0 (ACTUAL)
Number of arms: 6.0
Start date: 2019-06-13
Primary completion date: 2020-04-06
Completion date: 2021-01-15
Baseline population: Baseline analysis population included all participants who were randomized to the study and received at least one dose of the randomized study treatment.
Clinical trial NCT05297864: PARP Inhibition for Gliomas (PI-4G or π4g)
Official title: Phase II Trial of Niraparib in Patients With Recurrent Glioma
Acronym: OU-SCC-PI-4G
Sponsor: University of Oklahoma (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Funder terminated funding.
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-06-09
Primary completion date: 2023-11-14
Completion date: 2024-02-06
Plan to share individual participant data: NO